Announcements Trials
Browse Landscape

Phase

Phase 2 165Phase 1/2 73Phase 1 59Phase 3 42Phase NA 4Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 5Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 26Rituximab 17Etoposide 16Methotrexate 15Dexamethasone 15Cytarabine 15Vincristine 14Prednisone 11Doxorubicin 11Radiotherapy 10blinatumomab 8fludarabine 7Mercaptopurine 7Filgrastim 7Daunorubicin 7Asparaginase 7pegaspargase 6Granulocyte Colony-Stimulating Factor 6Methylprednisolone 5Drug Therapy 5Dasatinib 5venetoclax 4prednylidene 4etoposide phosphate 4deltacortene 4Trimethoprim, Sulfamethoxazole Drug Combination 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Busulfan 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lenalidomide × Lymphoid × Clear all
NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Celgene

Phase 2/3 Completed
111 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡